Four notes:
1. Evusheld involves the administration of two monoclonal antibodies: tixagevimab and cilagavimab. They’re meant to be administered as two separate and immediate intramuscular injections.
2. The FDA said one dose of Evusheld may be effective at preventing COVID-19 for six months.
3. The antibody cocktail was authorized only for people with moderately to severely compromised immune systems who may not mount an adequate immune response to vaccination, or for those with a history of severe adverse reactions to a COVID-19 vaccine and cannot receive one.
4. It’s only authorized for people who are not currently infected and who have not recently been exposed to a COVID-19-positive individual.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
